Dr Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.


An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients

Dr Neal Shore, Assoc. Prof. Neeraj Agarwal, and Prof. Steven Joniau provide their thoughts on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials. These slides and video cover recent trials including CHAARTED, STAMPEDE, and LATITUDE. We are given an update on combination trials and how these might improve patient care while moving away from monotherapy.

Emerging treatment options

Dr Shore gives a comprehensive introduction, outlining the need for improved treatment options in prostate cancer. Data from the CHAARTED trial is discussed, in which androgen ablation therapy is used with or without docetaxel chemotherapy for treatment of patients with metastatic prostate cancer. Drug efficacy of systemic therapy in advancing or metastatic prostate cancer is evaluated in the STAMPEDE trial. The LATITUDE trial examines androgen deprivation therapy with abiraterone acetate plus prednisone in newly diagnosed high-risk metastatic hormone-naïve prostate cancer patients. Dr Shore discusses survival benefits and hazard ratios (HRs) and addresses clinical questions regarding treatment protocols, how to monitor subpopulations of patients needing tailored care, and what decisions need to be made following castration-resistance.

The North American perspective in treating prostate cancer

Prof. Agarwal gives us the North American perspective and addresses what treatment options to offer patients in a backdrop of limited data comparing docetaxel chemotherapy to abiraterone acetate. The pros and cons of treatment options are covered as well as considerations in patient and practitioner choice. Addressed are future directions including the role of biomarkers in treatment choice.

The European perspective in treating prostate cancer

Finally, Prof. Joniau provides insight into the European perspective. He covers the European Association of Urology treatment guidelines, and treatment selection factors to be considered when deciding on whether to combine ADT with abiraterone or docetaxel. Highlighted are patients with oligo-metastatic disease, and how ongoing studies aim to address current gaps in knowledge when treating this patient group. This video with accompanying slides provides practical guidance to oncologists and urologists, and we hope you find it a useful resource for improving your clinical practice.

Steven Joniau graduated in Urology in 2002 at the Catholic University of Leuven. In 2003, he was appointed full-time staff member at the Dept. of Urology, University Hospitals Leuven after a 1-year fellowship at the University Hospital of Wales, Cardiff, UK. In July 2012, he obtained his PhD in Medical Sciences entitled ‘High-risk localized prostate cancer: the role of surgery and the development of clinical outcome prediction models’. In 2013, he was appointed Assistant Professor at the Catholic University of Leuven. His principal field of interest is the management of urological cancers. He is heavily involved in uro- oncological surgery and the multidisciplinary approach of pelvic cancers. He also leads numerous research projects at the University Hospitals Leuven, which focus on lymph node staging in prostate cancer, surgical management and biomarker development of high-risk prostate cancer, the natural history of premalignant lesions of the prostate, chemoprevention of prostate and bladder cancer, minimally invasive treatment of renal cell cancer and prostate cancer, etc. Steven Joniau is scientific secretary of the BVU (Belgische Vereniging voor Urologie), he is past- chairman of the Renal Cell Carcinoma Group of the Young Academic Urologists Working Party of the EAU, he is member of the EAU Guideline Panel on Prostate Cancer and the SIOG Prostate Cancer Guideline Panel. He is also a member of several international scientific societies: EAU, SIU (Société Internationale d’Urologie), SIOG (International Society of Geriatric Oncology) and EORTC GUCG (European Organisation for Research and Treatment of Cancer, Genito-Urinary Cancers Group). He is appointed Associate Editor of ‘The Journal of OncoPathology’. He is Editorial Advisory Board member of ‘The European Journal of Surgical oncology’, Editorial Board member of ‘The Open Prostate Cancer Journal’, ‘Archivo Italiano di Urologia e Andrologia’, ‘The Central European Journal of Urology’ and International Scientific Board member of ‘Archivos Españoles de Urología’. Steven Joniau has received several international awards, of which the First prize of the Urological Challenge Session, received at the 2010 European Urology Forum in Davos, Switzerland, the Crystal Matula Award 2011, received at the 2011 EAU annual congress in Vienna, Austria and the biannual Orion International Oncology Award 2011, received at the 2011 EAU annual congress in Vienna, Austria are the most prestigious. In the last 10 years, he has published >170 papers in peer-reviewed journals in the field of uro- oncology and minimally invasive surgery. He received the Prize for the Best Paper published on Clinical Research in the Urological Literature at the EAU annual congress in Stockholm. He authored several book chapters, he has been invited Faculty in over 85 international congresses and is a faculty member of the ESU (European School of Urology).
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.
podcast Podcast

Episode

4

of 4

episode
Oncology 
HCC podcast series part 4: Intermediate HCC – the evolving role of IO

Integrating multimodal approaches with multidisciplinary care

Experts
Dr Edward Kim, Dr Nina Sanford, Dr Mark Yarchoan, Oncology Brothers (Moderators)
Endorsed by
Blue Faery plus Global Liver Institute DiCE
ELPA
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca.
video Video
Oncology 
The evolving role of liquid biopsy in HR+/HER2- metastatic breast cancer

Exploring the impact of liquid biopsy in advanced breast cancer

Experts
Prof. Frédérique Penault-Llorca, Dr Aditya Bardia
Endorsed by
ISLB ICAN international cancer advocacy network Biomarker Collaborative
Exon20group
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Thermo Fisher Scientific.
animated-video Animated Video
Oncology Obstetrics and Gynecology 
Current treatment options in advanced/recurrent endometrial cancer

Exploring the impact of molecular subtypes 

Experts
Prof. Christian Marth
  • download Downloadable
    Resources
  • clock 7 MIN
  • calendar Jan 2025

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of or speakers involved in this programme.